Ausgabe 5/2021
Inhalt (13 Artikel)
The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
Henner Stege, Maximilian Haist, Ulrike Nikfarjam, Michael Schultheis, Jaqueline Heinz, Saskia Pemler, Carmen Loquai, Stephan Grabbe
Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Fausto Petrelli, Anna Maria Morelli, Andrea Luciani, Antonio Ghidini, Cinzia Solinas
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer
Kathleen N. Moore, David S. Hong, Manish R. Patel, Shubham Pant, Susanna V. Ulahannan, Suzanne Jones, Funda Meric-Bernstam, Judy S. Wang, Raid Aljumaily, Erika P. Hamilton, Erika S. Wittchen, Xuejing Wang, Aimee Bence Lin, Johanna C. Bendell
Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
Jiani Wang, Qingyuan Zhang, Qiao Li, Yuxin Mu, Jing Jing, Huiping Li, Wei Li, Jingfen Wang, Guohua Yu, Xian Wang, Quchang Ouyang, Jing Hao, Liang Lu, Li Zhou, Jin Guan, Qing Li, Binghe Xu
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Rachel M. Layman
Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Rachel Evans, Neil Hawkins, Pascale Dequen-O’Byrne, Charles McCrea, Dominic Muston, Christopher Gresty, Sameer R. Ghate, Lin Fan, Robert Hettle, Keith R. Abrams, Johann de Bono, Maha Hussain, Neeraj Agarwal
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study
Matteo Santoni, Francesco Massari, Enrique Grande, Giuseppe Procopio, Marc R. Matrana, Mimma Rizzo, Ugo De Giorgi, Umberto Basso, Michele Milella, Roberto Iacovelli, Gaetano Aurilio, Lorena Incorvaia, Sebastiano Buti, Orazio Caffo, Giuseppe Fornarini, Francesco Carrozza, Veronica Mollica, Alessandro Rizzo, Fady Farag, Javier Molina-Cerrillo, Nicola Battelli
A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab
Kunal Desai, Landon Brown, Wei Wei, Matthew Tucker, Chester Kao, Emily Kinsey, Brian Rini, Kathryn Beckermann, Tian Zhang, Moshe C. Ornstein
Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line
Ondřej Fiala, Pavel Ostašov, Aneta Rozsypalová, Milan Hora, Ondřej Šorejs, Jan Šustr, Barbora Bendová, Ivan Trávníček, Jan Filipovský, Jindřich Fínek, Tomáš Büchler
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience
Margherita Rimini, Changhoon Yoo, Sara Lonardi, Gianluca Masi, Alessandro Granito, Yeonghak Bang, Mario Domenico Rizzato, Caterina Vivaldi, Luca Ielasi, Hyung-Don Kim, Francesca Bergamo, Francesca Salani, Simona Leoni, Baek-Yeol Ryoo, Min-Hee Ryoo, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini
Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation
Haley E. Ramsey, Kristy Stengel, James C. Pino, Gretchen Johnston, Merrida Childress, Agnieszka E. Gorska, Pia M. Arrate, Londa Fuller, Matthew Villaume, Melissa A. Fischer, P. Brent Ferrell Jr., Caroline E. Roe, Jing Zou, Alexander L. R. Lubbock, Matthew Stubbs, Sandra Zinkel, Jonathan M. Irish, Carlos F. Lopez, Scott Hiebert, Michael R. Savona
Isatuximab: A Review of Its Use in Multiple Myeloma
James E. Frampton
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Yvette N. Lamb